Kennedy Capital Management’s Sutro Biopharma STRO Stock Holding History

Kennedy Capital Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,095	Closed	-$175K	–	744
2024 Q1	$175K	Buy	3,095 +110	+4%	+$4.86K	﹤0.01%	711
2023 Q4	$128K	Buy	+2,985	New	+$94.7K	﹤0.01%	679
2022 Q3	–	Sell	-11,444	Closed	-$596K	–	626
2022 Q2	$596K	Buy	11,444 +13	+0.1%	+$726	0.02%	526
2022 Q1	$940K	Sell	11,431 -1,362	-11%	-$130K	0.02%	508
2021 Q4	$1.9M	Sell	12,793 -386	-3%	-$69.2K	0.04%	457
2021 Q3	$2.49M	Sell	13,179 -38	-0.3%	-$7.22K	0.06%	447
2021 Q2	$2.46M	Sell	13,217 -912	-6%	-$178K	0.05%	471
2021 Q1	$3.22M	Sell	14,129 -899	-6%	-$213K	0.06%	454
2020 Q4	$3.26M	Buy	+15,028	New	+$2.49M	0.07%	433

Other funds holding STRO

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Kennedy Capital Management's STRO Position: Q2 2024 in Review

Kennedy Capital Management sold out of Sutro Biopharma (STRO) in Q2 2024, closing a stake of 3,095 shares — an estimated $175K sold.

Kennedy Capital Management first reported a position in STRO in Q4 2020 and held it in 9 quarters. The position peaked at $3.26M in Q4 2020. 119 funds tracked by Wall St. Rank hold STRO as of Q2 2024.

Kennedy Capital Management reported no remaining Sutro Biopharma position as of Q2 2024 after selling out during the quarter.
Kennedy Capital Management sold 3,095 Sutro Biopharma shares in Q2 2024, an estimated $175K.
Kennedy Capital Management first reported a position in Sutro Biopharma in Q4 2020 and held it in 9 quarters.
Kennedy Capital Management's Sutro Biopharma position peaked at $3.26M in Q4 2020.
119 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2024.

Based on Kennedy Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.